ClinicalTrials.gg
CompletedNCT05337137RELATIVITY-106Updated Oct 14, 2026Results posted

A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

A Phase 1/2 interventional study of Relatlimab and Nivolumab in Carcinoma, Hepatocellular, sponsored by Bristol-Myers Squibb. Completed at 61 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Updated Oct 14, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb — 3 open to participants now, 4 under way, 1 of them phase 3. Carcinoma, Hepatocellular · Bristol-Myers Squibb.

Enrollment
13th of 19
82 · median 198
Started
2022
the only one that year
Phase 1/2
7 of 21
2 open now
Registered
18th of 21
by date

Among the 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb, this one is the 13th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 1/2, and was the 18th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

3 of the 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).

03

Conditions studied

  • Carcinoma, Hepatocellular

Keywords

  • Hepatocellular Carcinoma
  • HCC
  • Liver Cancer
  • Relatlimab
  • Nivolumab
  • Bevacizumab
  • First line HCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed advanced/ hepatocellular carcinoma (HCC)
  • Naïve to systemic therapy for advanced/metastatic HCC (prior or adjuvant immunotherapy is permitted if recurrence occurs ≥ 6 months after treatment completion and the case is discussed with BMS medical team)
  • score of 5 or 6 (ie, Child-Pugh A)
  • (ECOG) performance status 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
  • Prior allogenic stem cell or solid organ transplantation
  • Untreated symptomatic central nervous system (CNS)
  • ascites as defined by:

    i) Prior ascites that required treatment and requires on-going prophylaxis, or ii) Current ascites requiring treatment

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Arm A: Relatlimab + Nivolumab + Bevacizumab

    Drug: Relatlimab · Drug: Nivolumab · Drug: Bevacizumab

  • Experimental
    Arm B: Placebo + Nivolumab + Bevacizumab

    Drug: Nivolumab · Drug: Bevacizumab · Other: Placebo

Interventions

  • Specified dose on specified days

    Also known as: BMS-986016

  • Specified dose on specified days

    Also known as: BMS-936558, Opdivo

  • Specified dose on specified days

    Also known as: Avastin

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities

    Bevacizumab DLTs: Include any AE causing \>42-day delay, GI perforation, nephrotic syndrome, Grade 3/4 infusion reactions, Death events, neutropenic fever, most non-hematologic toxicities (with specified exceptions), prolonged severe GI/electrolyte issues, significant fatigue, severe liver enzyme elevation, PRES/RPLS, severe hypertension or cardiac events, thromboembolism, major bleeding, wound complications, fistula, necrotizing fasciitis, and severe hematologic toxicity. Immunotherapy DLTs: Include severe immune-related events (eg, colitis, pneumonitis, uveitis), Grade 4 organ toxicities, serious hypersensitivity, prolonged/recurrent AEs, severe electrolyte/GI/fatigue events, Grade 5 events, severe hematologic, hepatic, neurologic, cardiac (myocarditis), and severe dermatologic reactions (eg, SJS/TEN, DRESS).

    Time frame: From Day 1 (first dose) untill 6 weeks post first dose

  2. Objective Response Rate (ORR) Assessed by BICR - All Comer Population

    Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)

  3. Objective Response Rate (ORR) Assessed by BICR - All EHSS No Population

    Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)

Secondary outcomes

  1. Progression-Free Survival (All Comer Population) Per BICR in Participants With LAG-3 Positive Status(≥1% by IHC)

    Progression free survival (PFS) is defined as time from on treatment to disease progression or death (whichever comes first). Disease progression is defined as Unequivocal progression of existing non-target lesions.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)

  2. Progression-Free Survival (All EHSS No Population) Per BICR in Participants With LAG-3 Positive Status(≥1% by IHC)

    Progression free survival (PFS) is defined as time from on treatment to disease progression or death (whichever comes first). Disease progression is defined as unequivocal progression of existing non-target lesions.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)

  3. Objective Response Rate (ORR) Per BICR - All Comer Population in Participants With LAG-3 Positive Status(≥1% by IHC)

    Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)

  4. Objective Response Rate (ORR) Per BICR - All EHSS No Population in Participants With LAG-3 Positive Status(≥1% by IHC)

    Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)

  5. Number of Participants With Adverse Events

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: From first dose (Day 1) to 30 days after last dose (up to approximately 36 months)

  6. Number of Participants With Select Adverse Events

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose (Day 1) to 30 days after last dose (up to approximately 36 months)

  7. Number of Participants With Immune Mediated Endocrine Adverse Events

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose (Day 1) to 30 days after last dose (up to approximately 36 months)

07

Results

Posted Oct 14, 2026

Participant flow

Participant flow — Overall Study
MilestoneRelatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + Bevacizumab
Started4240
Completed67
Not completed3633
Withdrew: Other reasons45
Withdrew: Withdrawal by subject12
Withdrew: Participant request to discontinue study41
Withdrew: Death43
Withdrew: Physician decision37
Withdrew: Lack of efficacy2015

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities

Bevacizumab DLTs: Include any AE causing \>42-day delay, GI perforation, nephrotic syndrome, Grade 3/4 infusion reactions, Death events, neutropenic fever, most non-hematologic toxicities (with specified exceptions), prolonged severe GI/electrolyte issues, significant fatigue, severe liver enzyme elevation, PRES/RPLS, severe hypertension or cardiac events, thromboembolism, major bleeding, wound complications, fistula, necrotizing fasciitis, and severe hematologic toxicity. Immunotherapy DLTs: Include severe immune-related events (eg, colitis, pneumonitis, uveitis), Grade 4 organ toxicities, serious hypersensitivity, prolonged/recurrent AEs, severe electrolyte/GI/fatigue events, Grade 5 events, severe hematologic, hepatic, neurologic, cardiac (myocarditis), and severe dermatologic reactions (eg, SJS/TEN, DRESS).

Time frame:
From Day 1 (first dose) untill 6 weeks post first dose
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities
ParticipantsRelatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + Bevacizumab
Number of Participants With Dose Limiting Toxicities01
PrimaryObjective Response Rate (ORR) Assessed by BICR - All Comer Population

Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Assessed by BICR - All Comer Population
percentage of participantsRelatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + Bevacizumab
Objective Response Rate (ORR) Assessed by BICR - All Comer Population31.0 (19.4 to 44.6)37.5 (24.7 to 51.7)
Statistical analysis
  • Relatlimab + Nivolumab + Bevacizumab vs Placebo + Nivolumab + Bevacizumab · Difference of ORR · Mean difference (final values): -6.5 · 90% CI -23.8 to 10.7
PrimaryObjective Response Rate (ORR) Assessed by BICR - All EHSS No Population

Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Assessed by BICR - All EHSS No Population
percentage of participantsRelatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + Bevacizumab
Objective Response Rate (ORR) Assessed by BICR - All EHSS No Population31.8 (16.0 to 51.5)44.4 (24.4 to 65.9)
Statistical analysis
  • Relatlimab + Nivolumab + Bevacizumab vs Placebo + Nivolumab + Bevacizumab · Difference of ORR · Mean difference (final values): -12.6 · 90% CI -37.9 to 12.6
SecondaryProgression-Free Survival (All Comer Population) Per BICR in Participants With LAG-3 Positive Status(≥1% by IHC)

Progression free survival (PFS) is defined as time from on treatment to disease progression or death (whichever comes first). Disease progression is defined as Unequivocal progression of existing non-target lesions.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
Reported as:
Median · months
Progression-Free Survival (All Comer Population) Per BICR in Participants With LAG-3 Positive Status(≥1% by IHC)
monthsRelatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + Bevacizumab
Progression-Free Survival (All Comer Population) Per BICR in Participants With LAG-3 Positive Status(≥1% by IHC)13.44 (6.77 to 19.38)12.62 (1.45 to NA)
SecondaryProgression-Free Survival (All EHSS No Population) Per BICR in Participants With LAG-3 Positive Status(≥1% by IHC)

Progression free survival (PFS) is defined as time from on treatment to disease progression or death (whichever comes first). Disease progression is defined as unequivocal progression of existing non-target lesions.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
Reported as:
Median · months
Progression-Free Survival (All EHSS No Population) Per BICR in Participants With LAG-3 Positive Status(≥1% by IHC)
monthsRelatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + Bevacizumab
Progression-Free Survival (All EHSS No Population) Per BICR in Participants With LAG-3 Positive Status(≥1% by IHC)14.92 (5.62 to NA)7.03 (1.41 to NA)
SecondaryObjective Response Rate (ORR) Per BICR - All Comer Population in Participants With LAG-3 Positive Status(≥1% by IHC)

Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Per BICR - All Comer Population in Participants With LAG-3 Positive Status(≥1% by IHC)
percentage of participantsRelatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + Bevacizumab
Objective Response Rate (ORR) Per BICR - All Comer Population in Participants With LAG-3 Positive Status(≥1% by IHC)53.8 (28.7 to 77.6)53.3 (30.0 to 75.6)
SecondaryObjective Response Rate (ORR) Per BICR - All EHSS No Population in Participants With LAG-3 Positive Status(≥1% by IHC)

Objective response rate (ORR) is defined as the percentage of participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on blinded independent central review (BICR) assessments using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Per BICR - All EHSS No Population in Participants With LAG-3 Positive Status(≥1% by IHC)
percentage of participantsRelatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + Bevacizumab
Objective Response Rate (ORR) Per BICR - All EHSS No Population in Participants With LAG-3 Positive Status(≥1% by IHC)40.0 (7.6 to 81.1)50.0 (19.3 to 80.7)
SecondaryNumber of Participants With Adverse Events

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
From first dose (Day 1) to 30 days after last dose (up to approximately 36 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsRelatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + Bevacizumab
Adverse Events4240
Serious Adverse Events2023
SecondaryNumber of Participants With Select Adverse Events

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose (Day 1) to 30 days after last dose (up to approximately 36 months)
Reported as:
Count of participants · Participants
Number of Participants With Select Adverse Events
ParticipantsRelatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + Bevacizumab
Gastrointestinal adverse event119
Hepatic adverse event99
Pulmonary adverse event21
Renal adverse event64
Skin adverse event1810
Hypersensitivity/infusion reaction12
SecondaryNumber of Participants With Immune Mediated Endocrine Adverse Events

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose (Day 1) to 30 days after last dose (up to approximately 36 months)
Reported as:
Count of participants · Participants
Number of Participants With Immune Mediated Endocrine Adverse Events
ParticipantsRelatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + Bevacizumab
Adrenal insufficiency33
Hypothyroidism80
Hyperthyroidism11

Adverse events

Collected over All cause mortality was collected up to approximately 42 months. AEs and SAEs were collected from first dose (Day 1) till Day 135 after last dose (up to approximately 38 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Relatlimab + Nivolumab + Bevacizumab29/42 (69%)25/42 (59.5%)42/42 (100%)
Placebo + Nivolumab + Bevacizumab18/40 (45%)26/40 (65%)38/40 (95%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventRelatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + Bevacizumab
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)7/422/40
Oesophageal varices haemorrhageGastrointestinal disorders3/422/40
General physical health deteriorationGeneral disorders3/420/40
AscitesGastrointestinal disorders2/422/40
HaematemesisGastrointestinal disorders0/422/40
Varices oesophagealGastrointestinal disorders0/422/40
SepsisInfections and infestations0/422/40
Hepatic encephalopathyNervous system disorders1/422/40
PyrexiaGeneral disorders2/421/40
AnaemiaBlood and lymphatic system disorders1/421/40
Most frequent other events
Showing 10 of 48
Most frequent other events
EventRelatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + Bevacizumab
HypertensionVascular disorders15/4211/40
DiarrhoeaGastrointestinal disorders11/429/40
ProteinuriaRenal and urinary disorders10/4210/40
PruritusSkin and subcutaneous tissue disorders10/424/40
PyrexiaGeneral disorders9/423/40
Decreased appetiteMetabolism and nutrition disorders9/426/40
ArthralgiaMusculoskeletal and connective tissue disorders4/428/40
ThrombocytopeniaBlood and lymphatic system disorders8/423/40
HypothyroidismEndocrine disorders8/422/40
RashSkin and subcutaneous tissue disorders8/425/40

Baseline characteristics

Age, Continuous
Age, Continuous(years)Relatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + BevacizumabTotal
Mean65.5 ± 10.4865.6 ± 10.0265.5 ± 10.20
Sex: Female, Male
Sex: Female, Male(Participants)Relatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + BevacizumabTotal
Female7411
Male353671
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Relatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + BevacizumabTotal
ASIAN221840
BLACK OR AFRICAN AMERICAN112
WHITE131831
NOT COLLECTED OR UNKNOWN639
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Relatlimab + Nivolumab + BevacizumabPlacebo + Nivolumab + BevacizumabTotal
HISPANIC OR LATINO538
NOT HISPANIC OR LATINO343468
UNKNOWN224
NOT REPORTED112
08

Study locations

61 sites
  • Local Institution - 0042
    Los Angeles, California 90033, United States
  • Local Institution - 0039
    Los Angeles, California 90095, United States
  • Local Institution - 0034
    San Francisco, California 94115, United States
  • Local Institution - 0030
    Washington D.C., District of Columbia 20007, United States
  • Local Institution - 0059
    Baltimore, Maryland 21231, United States
  • Local Institution - 0060
    Boston, Massachusetts 02114, United States
  • Local Institution - 0065
    Boston, Massachusetts 02215, United States
  • Local Institution - 0061
    New York, New York 10065, United States
  • Local Institution - 0062
    The Bronx, New York 10461, United States
  • Local Institution - 0033
    Milwaukee, Wisconsin 53226, United States
  • Local Institution - 0045
    Camperdown, New South Wales 2050, Australia
  • Local Institution - 0022
    Adelaide, South Australia 5000, Australia
  • Local Institution - 0026
    Heidelberg, Victoria 3084, Australia
  • Local Institution - 0013
    Melbourne, Victoria 3065, Australia
  • Local Institution - 0017
    Nedlands, Western Australia 6009, Australia
  • Local Institution - 0025
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution - 0009
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0064
    Guangzhou, Guangdong 510515, China
  • Local Institution - 0066
    Xi'an, Shan3xi 710700, China
  • Local Institution - 0021
    Avignon, Cedex 9 84918, France
  • Local Institution - 0012
    Grenoble, 38043, France
  • Local Institution - 0001
    Nice, 06202, France
  • Local Institution - 0002
    Reims, 51092, France
  • Local Institution - 0008
    Rennes, 35042, France
  • Local Institution - 0054
    Suresnes, 92151, France
  • Local Institution - 0051
    Düsseldorf, North Rhine-Westphalia 40225, Germany
  • Local Institution - 0035
    Frankfurt, 60590, Germany
  • Local Institution - 0057
    Mainz, 55131, Germany
  • Local Institution - 0055
    Munich, 81377, Germany
  • Local Institution - 0004
    Hong Kong, 0, Hong Kong
  • Local Institution - 0031
    Shatin, 999077, Hong Kong
  • Local Institution - 0036
    Milan, 20122, Italy
  • Local Institution - 0003
    Padova, 35128, Italy
  • Local Institution - 0010
    Roma, 00168, Italy
  • Local Institution - 0047
    Kashiwa-shi, Chiba 2778577, Japan
  • Local Institution - 0048
    Matsuyama, Ehime 7900024, Japan
  • Local Institution - 0058
    Kanazawa, Ishikawa-ken 9208641, Japan
  • Local Institution - 0050
    Yokohama, Kanagawa 2320024, Japan
  • Local Institution - 0041
    Sayama, Osaka 5898511, Japan
  • Local Institution - 0063
    Chuo-ku, Tokyo 104-0045, Japan
  • Local Institution - 0028
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-796, Poland
  • Local Institution - 0016
    Warsaw, Masovian Voivodeship 02-034, Poland
  • Local Institution - 0023
    Gdansk, 80-219, Poland
  • Local Institution - 0052
    Rio Piedras, PR 935, Puerto Rico
  • Local Institution - 0019
    San Juan, 00927, Puerto Rico
  • Local Institution - 0029
    Singapore, 168583, Singapore
  • Local Institution - 0027
    Singapore, 217562, Singapore
  • Local Institution - 0018
    Singapore, 308433, Singapore
  • Local Institution - 0044
    Singapore, 329563, Singapore
  • Local Institution - 0037
    Seongnam-si, Gyeonggido 13496, South Korea
  • Local Institution - 0056
    Seoul, 138-736, South Korea
  • Local Institution - 0032
    Santiago de Compostela, A Coruña 15706, Spain
  • Local Institution - 0007
    Santander, Cantabria 39008, Spain
  • Local Institution - 0067
    Madrid, Sede Madrid 28027, Spain
  • Local Institution - 0053
    Madrid, 28046, Spain
  • Local Institution - 0038
    Pamplona, 31008, Spain
  • Local Institution - 0040
    Zaragoza, 50009, Spain
  • Local Institution - 0043
    District Taichung City, Tai Zhong Shi 404, Taiwan
  • Local Institution - 0024
    Taichung, 40705, Taiwan
  • Local Institution - 0046
    Taipei, 10048, Taiwan
  • Local Institution - 0049
    Taipei, 11217, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jul 2025, 38 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's 38 months is below that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2022
First posted
Apr 20, 2022
StartActual
May 5, 2022
Primary completionActual
Jul 5, 2025
CompletionActual
Nov 18, 2025
Results first posted
Oct 14, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 14, 2026
Enrollment
83→82
Oct 14, 2026
Primary outcomes
1 edited, 2 added, 1 removed
What changed in the outcomes
  • EditedIncidenceNumber of dose-limiting toxicities (DLTs)Participants With Dose Limiting ToxicitiesTime frame: Up to 6 weeks → From Day 1 (first dose) untill 6 weeks post first dose
  • AddedObjective Response Rate (ORR) Assessed by BICR - All Comer PopulationTime frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
  • AddedObjective Response Rate (ORR) Assessed by BICR - All EHSS No PopulationTime frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
  • RemovedOverall Response Rate (ORR) by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Assessed up to 3 years
Oct 14, 2026
Documents
Secondary outcomes
1 edited, 6 added, 5 removed
What changed in the outcomes
  • EditedNumber of participants with adverse events (AEs)Participants With Adverse EventsTime frame: Up to 135 days after participant's last dose → From first dose (Day 1) to 30 days after last dose (up to approximately 36 months)
  • AddedProgression-Free Survival (All Comer Population) Per BICR in Participants With LAG-3 Positive Status(≥1% by IHC)Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
  • AddedProgression-Free Survival (All EHSS No Population) Per BICR in Participants With LAG-3 Positive Status(≥1% by IHC)Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
  • AddedObjective Response Rate (ORR) Per BICR - All Comer Population in Participants With LAG-3 Positive Status(≥1% by IHC)Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
  • AddedObjective Response Rate (ORR) Per BICR - All EHSS No Population in Participants With LAG-3 Positive Status(≥1% by IHC)Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
  • AddedNumber of Participants With Select Adverse EventsTime frame: From first dose (Day 1) to 30 days after last dose (up to approximately 36 months)
  • AddedNumber of Participants With Immune Mediated Endocrine Adverse EventsTime frame: From first dose (Day 1) to 30 days after last dose (up to approximately 36 months)
  • RemovedProgression Free Survival (PFS) by BICR per RECIST v1.1 in all randomized participants that are lymphocyte activation gene 3 (LAG-3) positiveTime frame: Assessed up to 3 years
  • RemovedPFS by BICR per RECIST v1.1 in all randomized participantsTime frame: Assessed up to 3 years
  • RemovedORR by BICR per RECIST v1.1 in all randomized participants that are LAG-3 positiveTime frame: Assessed up to 3 years
  • RemovedOverall Survival (OS) of all randomized participantsTime frame: Assessed up to 3 years
  • RemovedOS of all randomized participants that are LAG-3 positiveTime frame: Assessed up to 3 years
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Results posted
    Enrollment 83→82
    Primary outcomes 1 edited, 2 added, 1 removed
    What changed in the outcomes
    • EditedIncidenceNumber of dose-limiting toxicities (DLTs)Participants With Dose Limiting ToxicitiesTime frame: Up to 6 weeks → From Day 1 (first dose) untill 6 weeks post first dose
    • AddedObjective Response Rate (ORR) Assessed by BICR - All Comer PopulationTime frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
    • AddedObjective Response Rate (ORR) Assessed by BICR - All EHSS No PopulationTime frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
    • RemovedOverall Response Rate (ORR) by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Assessed up to 3 years
    Secondary outcomes 1 edited, 6 added, 5 removed
    What changed in the outcomes
    • EditedNumber of participants with adverse events (AEs)Participants With Adverse EventsTime frame: Up to 135 days after participant's last dose → From first dose (Day 1) to 30 days after last dose (up to approximately 36 months)
    • AddedProgression-Free Survival (All Comer Population) Per BICR in Participants With LAG-3 Positive Status(≥1% by IHC)Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
    • AddedProgression-Free Survival (All EHSS No Population) Per BICR in Participants With LAG-3 Positive Status(≥1% by IHC)Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
    • AddedObjective Response Rate (ORR) Per BICR - All Comer Population in Participants With LAG-3 Positive Status(≥1% by IHC)Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
    • AddedObjective Response Rate (ORR) Per BICR - All EHSS No Population in Participants With LAG-3 Positive Status(≥1% by IHC)Time frame: From first dose to the date of first objectively documented progression, per RECIST v1.1, or death due to any cause, whichever occurred first (up to approximately 3 years)
    • AddedNumber of Participants With Select Adverse EventsTime frame: From first dose (Day 1) to 30 days after last dose (up to approximately 36 months)
    • AddedNumber of Participants With Immune Mediated Endocrine Adverse EventsTime frame: From first dose (Day 1) to 30 days after last dose (up to approximately 36 months)
    • RemovedProgression Free Survival (PFS) by BICR per RECIST v1.1 in all randomized participants that are lymphocyte activation gene 3 (LAG-3) positiveTime frame: Assessed up to 3 years
    • RemovedPFS by BICR per RECIST v1.1 in all randomized participantsTime frame: Assessed up to 3 years
    • RemovedORR by BICR per RECIST v1.1 in all randomized participants that are LAG-3 positiveTime frame: Assessed up to 3 years
    • RemovedOverall Survival (OS) of all randomized participantsTime frame: Assessed up to 3 years
    • RemovedOS of all randomized participants that are LAG-3 positiveTime frame: Assessed up to 3 years
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05337137
Responsible party
Sponsor
First posted
Apr 20, 2022
Start date
May 5, 2022
Primary completion
Jul 5, 2025
Completion
Nov 18, 2025
Results posted
Oct 14, 2026
Last update
Oct 14, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relatlimab

Start the discussion